Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer

International Journal of Cancer

Volumn 133, Issue 9, 2013, Pages 2225-2233

  Zhan, Yang ^a,b   Cao, Bo ^a,b   Qi, Yanfeng ^b   Liu, Shuang ^b   Zhang, Qi ^b   Zhou, Weidong ^c   Xu, Duo ^a,b   Lu, Hua ^b   Sartor, Oliver ^b   Kong, Wei ^a   Zhang, Haitao ^a,b   Dong, Yan ^a,b  

^a JILIN UNIVERSITY   (China)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGE MASON UNIVERSITY   (United States)

Author keywords

androgen receptor; castration resistant prostate cancer; MDV3100; methylseleninic acid; methylselenocysteine

Indexed keywords

ANDROGEN RECEPTOR; ENZALUTAMIDE; METHYLSELENOL; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANDROGEN RECEPTOR; CASTRATION-RESISTANT PROSTATE CANCER; MDV3100; METHYLSELENINIC ACID; METHYLSELENOCYSTEINE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHROMATOGRAPHY, THIN LAYER; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; METHANOL; MICE; MICE, NUDE; ORCHIECTOMY; ORGANOSELENIUM COMPOUNDS; PHENYLTHIOHYDANTOIN; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84882668677     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28202     Document Type: Article

References (42)

1. Lamont KR, Tindall DJ,. Minireview: alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol 2011; 25: 897-907.
2. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90.
3. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97.
4. Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68: 5469-77.
5. Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 2305-13.
6. Hu R, Dunn TA, Wei S, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69: 16-22.
7. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-30.
8. Zhang X, Morrissey C, Sun S, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011; 6: e27970.
9. Hu R, Isaacs WB, Luo J,. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2011; 71: 1656-67.
10. Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72: 3457-62.
11. Hornberg E, Ylitalo EB, Crnalic S, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 2011; 6: e19059.
12. Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107: 16759-65.
13. Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2012; 73: 483-9.
14. Ip C,. Lessons from basic research in selenium and cancer prevention. J Nutr 1998; 128: 1845-54.
15. Dong Y, Lee SO, Zhang H, et al. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004; 64: 19-22.
16. Dong Y, Zhang H, Gao AC, et al. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Mol Cancer Ther 2005; 4: 1047-55.
17. Lee SO, Yeon CJ, Nadiminty N, et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate 2006; 66: 1070-5.
18. Chun JY, Nadiminty N, Lee SO, et al. Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer. Mol Cancer Ther 2006; 5: 913-18.
19. Ip C, Thompson HJ, Zhu Z, et al. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000; 60: 2882-6.
20. Marshall JR, Ip C, Romano K, et al. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer Prev Res (Phila) 2011; 4: 1938-44.
21. Hu H, Li GX, Wang L, et al. Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin. Clin Cancer Res 2008; 14: 1150-8.
22. Dong Y, Zhang H, Hawthorn L, et al. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 2003; 63: 52-9.
23. Jiang C, Wang Z, Ganther H, et al. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells. Cancer Res 2001; 61: 3062-70.
24. Li GX, Lee HJ, Wang Z, et al. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008; 29: 1005-12.
25. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301: 39-51.
26. Wang L, Bonorden MJ, Li GX, et al. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila) 2009; 2: 484-95.
27. Ohta Y, Kobayashi Y, Konishi S, et al. Speciation analysis of selenium metabolites in urine and breath by HPLC- and GC-inductively coupled plasma-MS after administration of selenomethionine and methylselenocysteine to rats. Chem Res Toxicol 2009; 22: 1795-801.
28. Chen Z, Zhang C, Wu D, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J 2011; 30: 2405-19.
29. Zhang C, Wang L, Wu D, et al. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res 2011; 71: 6738-48.
30. Yeh S, Chang C,. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 1996; 93: 5517-21.
31. Cao B, Liu X, Li J, et al. 20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor. Int J Cancer 2013; 132: 1277-87.
32. Cao S, Durrani FA, Rustum YM,. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004; 10: 2561-9.
33. Qi Y, Fu X, Xiong Z, et al. Methylseleninic acid enhances paclitaxel efficacy for the treatment of triple-negative breast cancer. PLoS One 2012; 7: e31539.
34. Jiang W, Jiang C, Pei H, et al. In vivo molecular mediators of cancer growth suppression and apoptosis by selenium in mammary and prostate models: lack of involvement of gadd genes. Mol Cancer Ther 2009; 8: 682-91.
35. Gleave ME, Hsieh JT, Wu HC, et al. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992; 52: 1598-605.
36. Chou TC, Talaly P,. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 1977; 252: 6438-42.
37. Tepper CG, Boucher DL, Ryan PE, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62: 6606-14.
38. Vichai V, Kirtikara K,. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006; 1: 1112-16.
39. Abdo M, Knapp S,. Mechanism of a redox coupling of seleninic acid with thiol. J Org Chem 2012; 77: 3433-8.
40. Faehl LG, Kice JL,. Oxidation of sulfides and phosphines by aromatic selenonic and seleninic acids. J Org Chem 1979; 44: 2357-61.
41. Zhou ZX, Lane MV, Kemppainen JA, et al. Specificity of ligand-dependent androgen receptor stabilization: receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 1995; 9: 208-18.
42. Yamashita S, Lai KP, Chuang KL, et al. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 2012; 14: 74-83.